MSFP
NBIX icon

Mark Sheptoff Financial Planning’s Neurocrine Biosciences NBIX Stock Holding History

Mark Sheptoff Financial Planning’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-37
Closed -$5K – 355
2020
Q2 		$5K Hold
37
– – ﹤0.01% 301
2020
Q1 		$3K Hold
37
– – ﹤0.01% 298
2019
Q4 		$4K Hold
37
– – ﹤0.01% 324
2019
Q3 		$3K Buy
+37
New +$3.46K ﹤0.01% 326

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Mark Sheptoff Financial Planning's NBIX Position: Q3 2020 in Review

Mark Sheptoff Financial Planning sold out of Neurocrine Biosciences (NBIX) in Q3 2020, closing a stake of 37 shares — an estimated $5K sold.

Mark Sheptoff Financial Planning first reported a position in NBIX in Q3 2019 and held it in 4 quarters. The position peaked at $5K in Q2 2020. 418 funds tracked by Wall St. Rank hold NBIX as of Q3 2020.

  • Mark Sheptoff Financial Planning reported no remaining Neurocrine Biosciences position as of Q3 2020 after selling out during the quarter.
  • Mark Sheptoff Financial Planning sold 37 Neurocrine Biosciences shares in Q3 2020, an estimated $5K.
  • Mark Sheptoff Financial Planning first reported a position in Neurocrine Biosciences in Q3 2019 and held it in 4 quarters.
  • Mark Sheptoff Financial Planning's Neurocrine Biosciences position peaked at $5K in Q2 2020.
  • 418 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2020.

Based on Mark Sheptoff Financial Planning's 13F filing for Q3 2020, filed 12 Nov 2020.